AstraZeneca (AZN) Given a $38.00 Price Target by BMO Capital Markets Analysts

AstraZeneca (NYSE:AZN) received a $38.00 target price from investment analysts at BMO Capital Markets in a note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the stock. BMO Capital Markets’ price target indicates a potential upside of 7.74% from the company’s current price.

A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday. JPMorgan Chase & Co. raised AstraZeneca from a “neutral” rating to an “overweight” rating in a report on Friday, December 29th. Leerink Swann raised their target price on AstraZeneca from $31.00 to $34.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Citigroup raised AstraZeneca to a “buy” rating in a report on Wednesday, October 18th. Finally, Cowen reaffirmed a “hold” rating and issued a $37.00 target price on shares of AstraZeneca in a report on Tuesday, October 17th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company’s stock. AstraZeneca has a consensus rating of “Hold” and an average price target of $34.20.

Shares of AstraZeneca (NYSE:AZN) opened at $35.27 on Wednesday. The firm has a market capitalization of $88,030.00, a price-to-earnings ratio of 25.19, a price-to-earnings-growth ratio of 3.44 and a beta of 0.76. AstraZeneca has a twelve month low of $26.51 and a twelve month high of $35.92. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09.

AstraZeneca (NYSE:AZN) last issued its earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.55. The firm had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $6 billion. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.32 EPS. equities research analysts expect that AstraZeneca will post 1.88 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Dorsey & Whitney Trust CO LLC raised its position in AstraZeneca by 0.7% during the 2nd quarter. Dorsey & Whitney Trust CO LLC now owns 13,315 shares of the company’s stock worth $454,000 after purchasing an additional 94 shares during the last quarter. Financial Counselors Inc. raised its position in AstraZeneca by 2.7% during the 2nd quarter. Financial Counselors Inc. now owns 6,871 shares of the company’s stock worth $234,000 after purchasing an additional 182 shares during the last quarter. FTB Advisors Inc. raised its position in AstraZeneca by 3.2% during the 2nd quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock worth $197,000 after purchasing an additional 200 shares during the last quarter. Logan Capital Management Inc. grew its holdings in AstraZeneca by 1.7% during the 2nd quarter. Logan Capital Management Inc. now owns 22,327 shares of the company’s stock worth $761,000 after acquiring an additional 377 shares during the period. Finally, Veritable L.P. grew its holdings in AstraZeneca by 6.5% during the 2nd quarter. Veritable L.P. now owns 6,877 shares of the company’s stock worth $234,000 after acquiring an additional 419 shares during the period. Institutional investors own 14.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “AstraZeneca (AZN) Given a $38.00 Price Target by BMO Capital Markets Analysts” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/11/astrazeneca-azn-given-a-38-00-price-target-by-bmo-capital-markets-analysts.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply